Clinical trials: Uveitis, Anterior
Non-infectious Anterior Uveitis
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
- Trial name
- NCT03131154
- Testing
- ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
- Where
- 27 sites in United States
- Volunteers
- 123 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Endogenous Anterior Uveitis
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
- Trial name
- NCT01201798
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Acute Anterior Uveitis
Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).
- Trial name
- NCT02482129
- Testing
- LME636 60 mg/mL ophthalmic solution, Dexamethasone 0.1% ophthalmic solution, LME636 Vehicle
- Volunteers
- 45 people
- Sponsor
- Alcon Research
Active Non-anterior, Non-infectious Uveitis
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Trial name
- NCT07552012
- Testing
- FXS5626 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Axial Spondylarthritis (axSpA)
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior…
- Trial name
- UP-FOR-U (NCT07018206)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- CARE ARTHRITIS LTD.
Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
- Trial name
- NCT00333996
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Allergan
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Anterior Uveitis
Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis
- Trial name
- NCT00823173
- Testing
- ESBA105
- Where
- 3 sites in Germany
- Volunteers
- 9 people
- Sponsor
- ESBATech AG
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU)
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.
- Trial name
- C-VIEW (NCT03020992)
- Testing
- Certolizumab Pegol
- Where
- 23 sites in Czechia, Germany and 3 more
- Volunteers
- 89 people
- Sponsor
- UCB Biopharma SRL
Non-infectious Anterior Uveitis
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
- Trial name
- EYETAC (NCT07285070)
- Testing
- Tacrolimus ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novaliq GmbH